Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462777 | 0.88 | RXFP1 (0.78) | KMT2AMEN1ADORA2BSMN1; SMN2RXFP1 | |
| SCHEMBL10113885 | 0.86 | KMT2A (0.71) | KMT2AMEN1ADORA2BSMN1; SMN2RXFP1 | |
| SCHEMBL10114162 | 0.85 | KMT2A (0.70) | KMT2AMEN1ADORA2BSMN1; SMN2RXFP1 | |
| SCHEMBL17744968 | 0.85 | RXFP1 (0.75) | KMT2AMEN1ADORA2BSMN1; SMN2RXFP1 | |
| Acefylline SCHEMBL18191994 | 0.84 | ADORA2B (1.00) | KMT2AMEN1ADORA2BSMN1; SMN2RXFP1 | |
| Acefylline SCHEMBL308514 | 0.84 | ADORA2B (1.00) | KMT2AMEN1ADORA2BSMN1; SMN2RXFP1 | |
| SCHEMBL11531219 | 0.84 | ADORA2B (0.78) | KMT2AMEN1ADORA2BSMN1; SMN2RXFP1 | |
| SCHEMBL12260506 | 0.84 | RXFP1 (0.69) | KMT2AMEN1ADORA2BSMN1; SMN2RXFP1 | |
| SCHEMBL10178027 | 0.83 | SMN1; SMN2 (1.00) | KMT2AMEN1ADORA2BSMN1; SMN2RXFP1 | |
| SCHEMBL10114347 | 0.83 | KMT2A (0.82) | KMT2AMEN1ADORA2BSMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951073-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951073-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC (US) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | KMT2A 2953/4885MEN1 1785/4885ADORA2B 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.